Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | Datopotamab deruxtecan + Durvalumab |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Datopotamab deruxtecan | Dato-DXd|DS1062a|DS 1062a|DS-1062a | TROP2 Antibody 7 | Datopotamab deruxtecan (DS-1062a) is an antibody-drug conjugate comprising an antibody that targets TROP2 linked to the topoisomerase I inhibitor DXd, which may induce apoptosis and inhibit tumor growth (PMID: 34413126). | |
| Durvalumab | Imfinzi | MEDI4736 | Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 117 | Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, in combination with Imjudo (tremelimumab) and platinum-based chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) without sensitizing EGFR or ALK mutations, in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer, in combination with cisplatin and gemcitabine in patients with locally advanced or metastatic biliary tract cancer, and in combination with Imjudo (tremelimumab) in adult patients with unresectable hepatocellular carcinoma (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06103864 | Phase III | Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Datopotamab deruxtecan + Durvalumab Datopotamab deruxtecan Carboplatin + Gemcitabine + Pembrolizumab | A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 15 |
| NCT04612751 | Phase I | Datopotamab deruxtecan + Durvalumab AZD2936 + Carboplatin + Datopotamab deruxtecan AZD2936 + Datopotamab deruxtecan Carboplatin + Datopotamab deruxtecan + Durvalumab Datopotamab deruxtecan + MEDI5752 Carboplatin + Datopotamab deruxtecan + MEDI5752 | Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung04) | Recruiting | USA | ITA | FRA | ESP | BEL | 5 |
| NCT05489211 | Phase II | Capecitabine + Datopotamab deruxtecan AZD5305 + Datopotamab deruxtecan + Durvalumab Capecitabine + Datopotamab deruxtecan + Nivolumab Carboplatin + Datopotamab deruxtecan Datopotamab deruxtecan + Fluorouracil AZD5305 + Datopotamab deruxtecan Datopotamab deruxtecan + Durvalumab Datopotamab deruxtecan + Fluorouracil + Nivolumab Bevacizumab + Datopotamab deruxtecan + Fluorouracil + Leucovorin Bevacizumab + Capecitabine + Datopotamab deruxtecan Datopotamab deruxtecan | Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | 7 |
| NCT05629585 | Phase III | Datopotamab deruxtecan Capecitabine + Pembrolizumab Datopotamab deruxtecan + Durvalumab | A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | 9 |
| NCT06112379 | Phase III | Carboplatin + Paclitaxel Cyclophosphamide + Epirubicin + Paclitaxel Capecitabine Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel Cyclophosphamide + Doxorubicin + Pembrolizumab Cyclophosphamide + Epirubicin + Pembrolizumab Datopotamab deruxtecan + Durvalumab Cyclophosphamide + Doxorubicin + Paclitaxel Carboplatin + Paclitaxel + Pembrolizumab | A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 16 |
CKB BOOST